Best answer:

Answer by bmac
FDA’s Center for Drug Evaluation and Research (CDER).

http://www.fda.gov/cder/index.html

Give your answer to this question below!

Technorati Tags: anyone, coming, Drugs, Generic, Help, know, tells, thanks.., upcoming, website

Question by Tony: Should I go back to college now?
Lots of stuff has happened in my wee little life. Parents were drug heads, grew up with my maternal grandparents both passed away by the time I was 16, then lived with paternal grandmother till 18. My grandmother(mom’s mother) was diagnosed with a brain tumor and she was my best friend and always wanted me to strive for the best in all things and I did my best to help her through radiation treatments and brain surgeries and she is now gone. My mother all throughout my childhood was in and out of jail, my father too. They finally would get stable and tug on me to come and live with them which would mean I’d leave my grandparents behind. My mother is in prison now, and my father is a house “dad,” while he is with a wonderful, very accomplished woman he baby-sits and helps at the house. Anyhoo, I always participated in sports, and strived for exceptional grades in fact, I graduated second in my class. I had 15 hours of college credit and I went big and shipped off to UT Austin. I guess I was supposed to be the God-child of the family. Church events, sport events, community events, top of my class, going to UT gonna become an anesthesiologist and everything great! Well…I made it to UT…started off fine and was shaken. I had all A’s for the first month…B’s second month…and 3rd F’S! I went to office hours, studied with friends, went to tutors. 500 pages to be read(write two essays over and take a test by Friday) a week, massive homework in statistics every night with a mini-test every friday…constantly making presentations and preparing for that massive 20 page research paper in another class…and worrying about the ONLY 4 tests i had the in the other class. I was overwhelmed, scared, and alone? I would study for 100 hours(no exaggeration) at least 10 hrs a day for 10 days for one test that i made a 55 on. That happened on three occasions…so it was like a horrible nightmare i couldn’t comprehend the material no matter how hard I tried, was depressed, had anxiety attacks, lost 24 pounds, and went to the mental health center on campus but felt like I got the whole generic “how do you “FEEL” about that psychological treatment.” Nehoo, dropped out about a month before finals right after finding out i had failed 2 of my classes. (not to mention was fighting with my family because to THEM I WAS GOING TO GRADUATE WITH HONORS!).
-anyways, after all that..I really want to get back into school. I took the next semester off, went back in the fall of last year barely scraped a C out of one class and a D out of the other(easy classes). I guess I lost my motivation. I lazily didn’t get signed up for classes this spring…and am now working a part-time job. I had a really hard time with those classes last fall…I would get super anxious about easy tests and assignments and my UT college experience would come back and haunt me, get dreams about it and all. I mean is there still hope? After 4 F’s in classes at my previous university(all a’s from the community college I attended back home), and the C and D at this community college. Is there a way I can still attend finish it out and go to nursing school like I had intended all along? I feel like there’s no hope. And this time I want to go on MY wants and dreams not my parents and families. Sorry it’s so long…guess my original question sums it up should I still go back and even if I do will i make it far?

Best answer:

Answer by betterthanyou17
nope

What do you think? Answer below!

Technorati Tags: back, college, Should

Dublin (PRWEB) June 26, 2005

Research and Markets (http://www.researchandmarkets.com/reports/c19706) has announced the addition of Corporate Focus Healthcare: GlaxoSmithKline Q1 2005 to their offering.

Problems continue for GlaxoSmithKline. The company delivered a poor set of results for 2004. While this was said to be largely due to competition from generic medicines in the pharmaceutical sector, the company’s “promising” new product pipeline is not delivering products quick enough to fill this gap.

Acquisitions

GlaxoSmithKline has regained the sales and marketing rights to five US prescription-only dermatology products from Elan Pharmaceuticals. The five brands are: Aclovate, Cutivate, Emgel, Oxistat and Temovate and have sales of around $ 35 million. Elan had licensed the brands from Glaxo Wellcome but decided against extending the agreement as it is withdrawing from dermatology. GlaxoSmithKline says that the brands, although prescription, make an excellent fit with the OTC brands in the Oxy portfolio and with the Abreva cold sore cream..

Warning in Canada

GlaxoSmithKline has warned wholesalers and retailers in Canada that they have to cease supplying prescription drugs to US patients as they are substantially cheaper in Canada. GSK says that its action is because of safety concerns for consumers who could be receiving drugs that are damaged during shipment or the prescription of which is not properly supervised by a doctor. The principal target of GSK’s action is Web-based pharmacies. Annual sales of prescription drugs to the US from Canada’s Manitoba area are estimated at some £300 million. Ten leading US and Canadian healthcare and business organisations started a national advertising campaign in the New York Times that encouraged consumers to look to reverse the ban. The advertisement also encouraged them to sell any GSK stock that they owned and to switch from GSK OTC products to comparable brands from other companies.

Challenges in generics

The FDA has received applications from companies that are looking to start manufacture of generic versions of the migraine drug Imitrex and herpes drug Valtrex. The patent for Valtrex runs until 2009 while Imitrex lasts until 2008.

GlaxoSmithKline still has some breathing space before these drugs are vulnerable to generics.

The GlaxoSmithKline newsletter covers the global consumer healthcare activities of GlaxoSmithKline during the first quarter of 2005.

Topics covered:

Communications.

Nine-month sales fall.

Acquisitions & Disposals.

Executive changes.

Communications & agency news.

Smoking Cessation.

Oral Care.

Functional foods.

Other brands

For more information visit http://www.researchandmarkets.com/reports/c19706

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

###

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Technorati Tags: 2005, Activities, Consumer, GlaxoSmithKline, Global, Healthcare, Markets, Research, Study

(PRWEB) July 23, 2005

More information on the Polish pharmaceutical and healthcare sector is available in the latest PMR report: “Pharmaceutical and healthcare market in Poland 2005”, published in July 2005.

The report provides a complete review of Poland’s pharmaceuticals market, including data for 2001-2004 and three-year market projections.

All statistics are presented both in value and volume, and are broken down by the following market segments:

-Rx, OTC and hospital;

-brand name and generic;

-domestically manufactured and imported.

Detailed data on 14 main ATC drug categories, in 90 sub-categories, is also included.

Future trends of domestic pharmaceutical firms are forecasted together with an in-depth look at the reasons why these companies started to flourish in 2004.

On top of in-depth analyses on the current condition of the domestic pharmaceutical sector (which considers employment, revenue, profit and profitability), the report sets out a comprehensive presentation of various aspects of the sector’s operation in Poland, covering: drug distribution, research and development and the climate for innovation, foreign investment and clinical research. Moreover, details as to the legal environment, with a strong focus on drug registration, marketing authorisation and advertising of medicinal products in Poland are covered.

As an added feature to the pharmaceutical market study, the report presents the general structure, key figures and financing of the healthcare sector in Poland, together with specific analyses on the private medical segment. The 20 top pharmaceutical markets players are ranked as to both value and volume, offering varied comparative bases.

More information about the report is available on: http://www.pmrpublications.com/index.php?id_rap=3038

Questions about ordering? Contact our sales department:

tel. /48 12/ 410 21 10

fax. /48 12/ 413 40 12

e-mail: sales@pmrpublications.com

www: pmrpublications.com

Customer Service hours: 8:00am to 5:00pm CET Monday through Friday.

Sign up for free headlines about the Polish Pharmaceutical market at http://www.pharmapoland.com

About PMR

PMR Ltd, is a British American publishing, consulting and market research company heaquartered in Cracow, Poland. PMR has been providing news and analysis, advice and services to international businesses interested in Central and Eastern Europe since 1995. With 44 full time staff, Google top ranked web sites and ten years of experience, PMR is one of the largest companies of its type in the region.

###

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Technorati Tags: Healthcare, Market, pharmaceutical, Poland, Report

Vancouver, BC (PRWEB) September 27, 2005

One Person Health Inc., an expert in online comparison health, today unveils HealthPricer.com, a ‘comparison shopping’ site focused on the healthcare products market. HealthPricer.com provides visitors with the most comprehensive product and ingredient information available on the internet together with the ability to compare features and pricing for over 13,000 dietary supplement products at over 40 of the Internet’s most trusted and respected vitamin stores.

“We’re launching our site at a time when health costs are rising for consumers, insurers and government. The proactive health consumer has emerged and is looking to the Internet as a source for information and purchasing power,” says George Fleming, CEO of OnePersonHealth. “E-health consumers require in-depth, science-based information to help them buy the products and services that fit their personal needs. There isn’t a market that is more confusing and complicated or one where quality and pricing is inconsistent. With the launch ofHealthPricer.com online shoppers can now shop with confidence and find the nutritional products they need at better prices.”

One source for purchasing power

With 49% of US consumers taking some form of nutraceutical product (American Dietetic Association), HealthPricer.com is initially focusing on nutrition and dietary supplements. The web site is easy to use and navigate, giving shoppers the ability to search, sort and compare supplements based on detailed product information, including dosage, health category, brand, Internet retailer, product certification and specialty science-based features, such as the ability to sort for products that are animal free, yeast free, gluten/wheat free and sugar free. Based on search criteria indicated by the shopper, HealthPricer.com searches the Internet’s top online retailers to find the exact products the shopper is looking for. From a list of the products that match these criteria, the shopper is then able to select those they’d like to price compare. Once a choice has been made HealthPricer.com directly drops those items into a shopping basket at the online health retailer of choice and the purchase is completed. HealthPricer.com will soon expand into other areas of health and wellness including pharmaceuticals and generic drugs, OTC drugs, sports supplements, cosmetics, skin care products and local comparison shopping for health products and services.

A trusted advisor of quality products

Recognizing that consumers are confused by fragmented and contradictory health information online, HealthPricer.com draws on the company’s vast collection of in-depth and science-based health and wellness information. OnePersonHealth has been leading the market by combining science-based nutritional health assessments with product recommendations to deliver affordable and accurate personalized nutritional healthcare solutions. HealthPricer.com builds on that experience and expertise and provides consumers with trusted health information together with comparison e-commerce.

In its efforts to better inform consumers of the quality of supplements, HealthPricer.com contains an entire section on supplement certifications and how shoppers can identify top quality products. Third party certification bodies such as USP, NNFA, and NSF have developed standards regulations that evaluate the quality of supplement products and manufacturers: their ingredients, dosage levels, label claims and manufacturing facilities. Every supplement on the site that has been certified, or is manufactured by a certified manufacturer, is identified by its corresponding seal to help shoppers choose from quality products.

Partnered with trusted online health retailers

Further living up to its promise of trusted health product comparison shopping, HealthPricer.com has partnered with over 40 of the Internet’s most trusted and respected vitamin stores. This allows HealthPricer.com to offer detailed product information and comparison on over 13,000 products.

Unique Shopping Features

HealthPricer.com presents a number of industry-first comparison shopping features designed specifically for the personal healthcare products market:

    ShopMatchingTM – a feature that automatically searches for products closely matching in ingredient, form of ingredient, dosage and content, which are available at lower prices;

    Shopping List PricingTM – allows consumers to create and comparison shop a shopping list of different products simultaneously.

    Unique filtering options – recognizing that every consumer will have different product preferences, the site allows the shopper to filter search results to easily find products that have a certain dosage of one ingredient, are animal free and dairy free or products that only have a certain designated certification.

    Supplement certification feature – HealthPricer.com’s third party certification feature allows the consumer to examine the certifications of the products they purchase.

In the near future, HealthPricer.com will also include consumer ratings and reviews through HealthPinions.com as well as provide a sign-up service that notifies registered members of better deals and product advice based on their personal settings and shopping experiences.

About OnePersonHealth

One Person Health http://www.onepersonhealth.com is a leader in the emerging field of Comparison Health. The Company’s unique approach and patent-pending technologies are driven by an underlying philosophy that in healthcare, “One Size Does Not Fit All”. Led by a proven management team of scientists and e-commerce professionals, OPH is commercializing its range of online and evidenced based health assessment programs, personalized product recommendations and comparison shopping technologies to consumers, healthcare practitioners and corporate partners in the US marketplace. One Person Health is a publicly traded company listed on the TSX Venture Exchange under the symbol TSXv-OPH.

# # #

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Related Generic Otc Drugs Press Releases

Technorati Tags: 13000, Comparison, Destination, Dietary, from, HealthPricer.com, Launch, offers, online, Over, Products, Retailers, Shop, Shoppers, Supplement

Dublin (PRWEB) January 27, 2006

Research and Markets (http://www.researchandmarkets.com/reports/c31614) has announced the addition of Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2005 to their offering.

The first quarter of 2005 was relatively quiet in the pricing, reimbursement, and prescribing environments of the worlds major pharmaceutical markets. The United States continued the implementation of the Medicare Modernization Act; the acts new prescription drug benefit is expected to give a substantial boost to pharmaceutical sales. At the same time, some members of Congress, state governments, and large employers pursued measures to reduce prescription drug prices in the United States. Several leading pharmaceutical companies responded to growing criticism of their prices by launching a new drug discount card. In Europe, governments sought ways to refine their well-established cost-containment strategies. Reference pricing provoked controversy in France and Germany, and the relatively underdeveloped generics markets of Southern Europe continued to grow. In Japan, industry observers saw signs of increasing pressure for reform of the pricing and reimbursement system.

Business Implications

The new Medicare prescription drug benefit is scheduled to begin operation on January 1, 2006. Prescription drug plans (PDPs) will be required to cover at least two drugs in each therapeutic category and pharmacological class. However, if a given category or class contains only two drugs, the PDP may limit coverage to a single agent within that category or class. Plans will not be obliged to cover off-label prescribing, and they will be permitted to use mechanisms such as prior authorization, step therapy protocols, generics substitution, and quantity limits to restrict access to certain drugs. PDPs will have to promote the use of generics by requiring the display of information on less expensive generic versions of a drug (if available) at the point of sale.

The pressure to legalize drug importation in the United States may become irresistible in the coming months. Two drug importation bills have been revived in Congress. A sponsor of one of the bills predicted that legislation to legalize drug importation will be passed by a margin of 75-25 votes, a majority that would make it difficult for the Bush administration to maintain its opposition. The pharmaceutical industry’s best hope of avoiding massive drug importation in the United States may be that Canada will act to ban this trade and that other potential parallel export markets will follow suit to protect their pharmaceutical supply systems.

The European Commission recently reaffirmed its resolve to implement the recommendations of the G10 Medicines Group. If the commission keeps its word, manufacturers can look forward to faster registration and market access for innovative drugs, streamlined pricing and reimbursement decisions at the member-state level, free pricing for drugs that are not purchased or reimbursed by member states, easier Rx-to-OTC switching and the freedom to continue using the same trademark for drugs switched to nonprescription status, the abolition of restrictions on the advertising of nonprescription medicines, and the introduction of measures to limit parallel imports from new member states in Central and Eastern Europe.

The impact of Germany’s expanded and more aggressive reference pricing system will be studied with interest not just in that country but throughout Europe. Many governments have followed the lead that Germany set in 1989 by introducing reference pricing, but none have been as bold as the pioneer of this approach to cost containment. Pfizer and other companies that have taken legal action against reference pricing decisions will anxiously wait to see the outcome of their lawsuits in Germany. The pharmaceutical industry as a whole will anxiously wait to see if other European governments decide to extend reference pricing to patent-protected drugs.

For more information visit http://www.researchandmarkets.com/reports/c31614

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

###

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Technorati Tags: Become, coming, drug, Importation, Irresistible, Legalize, Months, Pressure, States, United

Dublin (PRWEB) January 28, 2006

Research and Markets (http://www.researchandmarkets.com/reports/c31675) has announced the addition of The Role of Self-Medication in Cost-Containment in the United States to their offering

With sales in 2003 estimated at $ 17.5 billion, the U.S. market for over-the-counter (OTC) drugs is by far the largest in the world, but it is arguably far from being the most dynamic self-medication market. The U.S. markets sluggish performance is attributable in part to the very cautious attitude of the FDA toward the reclassification of prescription drugs as nonprescription medicines, a process known as “Rx-to-OTC switching.” However, recent statements made by the FDA indicate that its attitude toward Rx-to-OTC switching is about to change.

We begin this report by considering the perspectives on self-medication of three major stakeholder groups: consumers, payers, and manufacturers, plus the position of the FDA. We then examine the cost-containment implications of Rx-to-OTC switching in two drug classes that have had recent switch approvals (nonsedating antihistamines and proton pump inhibitors) and two classes that may see switches in the near future (statins and obesity therapies). We conclude with a brief assessment of the outlook and implications for the pharmaceutical industry.

Business Implications

Although the default status of medicines in the United States is nonprescription, the Food and Drug Administration (FDA) has traditionally been very cautious in regard to Rx-to- OTC switching (i.e., the reclassification of prescription drugs as nonprescription medicines). Far fewer compounds are available in OTC form in the United States than in the other major self-medication markets. However, the FDA has stated that it intends “to become more proactive in recommending key potential switches.”

Given that prescription drug prices are generally significantly higher than the prices of comparable OTC medicines, manufacturers usually have a vested interest in maintaining the prescription status of their new chemical entities as long as possible. However, as a drug approaches patent expiration and the threat of generics competition, it may be advantageous for the manufacturer to switch the drug to OTC status as a way of extending its life cycle. The timing of the switch is crucial: it should be early enough to develop consumer loyalty to the OTC brand but late enough to exploit the full sales potential of prescription sales.

When a drug is switched to OTC status, health plans often end reimbursement of other drugs within the same class or move these drugs to a higher formulary tier that incurs copayments higher than the OTC drug’s retail price. On average, copayments for third-tier drugs (i.e., nonpreferred brands) exceed $ 30 per month. The substantially lower prices of OTC drugs compared with competing prescription drugs have persuaded many health plans to add certain switched drugs to their formularies, often in a new tier that is subject to a very modest copayment (e.g., $ 5). According to a recent managed care survey, 31.5% of HMOs covered at least some OTC medicines in 2003.

Recent FDA judgments suggest that the pharmaceutical industry may need to be somewhat bolder in its dosing proposals in switch applications. In the past, manufacturers have assumed that reducing the dosing from standard prescription levels would enhance their prospects of succeeding with their switch applications, but the opposite has been the case in some instances. The FDA has shown that it is unwilling to approve switches that may use subtherapeutic dosing.

For more information visit http://www.researchandmarkets.com/reports/c31675

Source: Decision Resources, Inc.

Laura Wood

Senior Manager

Research and Markets

Fax: +353 1 4100 980

###

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Technorati Tags: Drugs, Largest, Market, overthecounter, States, United, World

(PRWEB) February 3, 2006

In 2004, seven GI drugs achieved blockbuster revenues, with the dominant class being the proton pump inhibitors. Visiongain concludes that the GI market is going through a period of transition, with generic competition and OTC switching having a profound effect on the market. By 2011, total revenues for the leading GI drugs are likely to have declined to approximately $ 11 billion worldwide.

Clearly, the GI market is facing great challenges in terms of internal competition and patent expiration, with a mounting generic threat. There are also unmet needs that provide commercial opportunities. This visiongain report examines the GI market critically through a comprehensive review of available information, including that from commercial databases, consultation with the industry, company reports, business/industry news and consultation with international experts on GI disorders. Visiongain applied techniques such as financial forecasting, SWOT analysis and the assessment of unmet needs to provide a comprehensive market report with detailed analyses and informed opinion.

In particular, this visiongain report concentrates on revenue trends in the world gastrointestinal market between 2005-2011, patent expiry and generic substitution, an assessment of prescription-to-OTC switching and lifecycle management strategies. Furthermore, the report covers pipeline products, with an analysis of the prospects for these agents.

Notes for editors:

To receive your complimentary overview of this report please send an email to Sara Peerun sara.peerun@visiongain.com, telephone Sara on +44 (0) 20 8767 6711 or visit the media section on http://www.visiongainintelligence.com/reportDetail.aspx?reportId=1272&adSelection=Y&industryIdL1=1005. Please include your full name, title of publication, contact telephone number, email, and details of where you saw this release. Upon receipt of this information, an overview will be emailed to you.

Background:

Visiongain is one of the fastest growing and most innovative independent media companies in Europe today. Based in London, UK, visiongain produce a host of business-2-business conferences, newsletters, management reports and E-Zines focusing on the Financial markets, the Pharmaceutical, Telecoms industries and the Defence sector.

http://www.visiongainintelligence.com

###

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

More Generic Otc Drugs Press Releases

Technorati Tags: 'With, Affecting, Commercial, generation, Market, mounting, pressures, reconsidering, Report, revenue, says, Strategies, Visiongain

Dublin (PRWEB) April 6, 2006

Research and Markets (http://www.researchandmarkets.com/reports/c31675) has announced the addition of The Role of Self-Medication in Cost-Containment in the United States to their offering

With sales in 2003 estimated at $ 17.5 billion, the U.S. market for over-the-counter (OTC) drugs is by far the largest in the world, but it is arguably far from being the most dynamic self-medication market. The U.S. markets sluggish performance is attributable in part to the very cautious attitude of the FDA toward the reclassification of prescription drugs as nonprescription medicines, a process known as “Rx-to-OTC switching.” However, recent statements made by the FDA indicate that its attitude toward Rx-to-OTC switching is about to change.

We begin this report by considering the perspectives on self-medication of three major stakeholder groups: consumers, payers, and manufacturers, plus the position of the FDA. We then examine the cost-containment implications of Rx-to-OTC switching in two drug classes that have had recent switch approvals (nonsedating antihistamines and proton pump inhibitors) and two classes that may see switches in the near future (statins and obesity therapies). We conclude with a brief assessment of the outlook and implications for the pharmaceutical industry.

Business Implications

Although the default status of medicines in the United States is nonprescription, the Food and Drug Administration (FDA) has traditionally been very cautious in regard to Rx-to- OTC switching (i.e., the reclassification of prescription drugs as nonprescription medicines). Far fewer compounds are available in OTC form in the United States than in the other major self-medication markets. However, the FDA has stated that it intends “to become more proactive in recommending key potential switches.”

Given that prescription drug prices are generally significantly higher than the prices of comparable OTC medicines, manufacturers usually have a vested interest in maintaining the prescription status of their new chemical entities as long as possible. However, as a drug approaches patent expiration and the threat of generics competition, it may be advantageous for the manufacturer to switch the drug to OTC status as a way of extending its life cycle. The timing of the switch is crucial: it should be early enough to develop consumer loyalty to the OTC brand but late enough to exploit the full sales potential of prescription sales.

When a drug is switched to OTC status, health plans often end reimbursement of other drugs within the same class or move these drugs to a higher formulary tier that incurs copayments higher than the OTC drug’s retail price. On average, copayments for third-tier drugs (i.e., nonpreferred brands) exceed $ 30 per month. The substantially lower prices of OTC drugs compared with competing prescription drugs have persuaded many health plans to add certain switched drugs to their formularies, often in a new tier that is subject to a very modest copayment (e.g., $ 5). According to a recent managed care survey, 31.5% of HMOs covered at least some OTC medicines in 2003.

Recent FDA judgments suggest that the pharmaceutical industry may need to be somewhat bolder in its dosing proposals in switch applications. In the past, manufacturers have assumed that reducing the dosing from standard prescription levels would enhance their prospects of succeeding with their switch applications, but the opposite has been the case in some instances. The FDA has shown that it is unwilling to approve switches that may use subtherapeutic dosing.

For more information visit http://www.researchandmarkets.com/reports/c31675

Source: Decision Resources, Inc.

Laura Wood

Senior Manager

Research and Markets

Fax: +353 1 4100 980

###

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

More Generic Otc Drugs Press Releases

Technorati Tags: Applications, Bolder, Dosing, Industry, Judgments, need, pharmaceutical, Proposals, Recent, Somewhat, States, Suggest, Switch, United

Dublin (PRWEB) August 18, 2006

Research and Markets (http://www.researchandmarkets.com/reports/c40749) has announced the addition of Sawai Pharmaceuticals Generics Company Intelligence Report to their offering.

These generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company’s active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

The easy and cost effective way to monitor developments in leading generic drug industry players.

Generics Company Reports are packed with facts, figures and statistics, providing you with the most thorough ongoing monitoring of the important generic companies. From financial performance to litigation, no other service provides such comprehensive insight to the companies driving growth in this rapidly expanding area of the pharmaceutical industry.

Each report is updated and issued every quarter. This ongoing monitoring and regular delivery ensures that developments are incorporated into the relevant reports. This vigilance ensures that whether it’s the latest deals, ANDAs, alliances or litigation you can assess the impact of the development in the context of the company, its competitors and the broader market.

Use Generic Company Reports to:

Evaluate the competitive operating environment.

Identify which companies are applying for ANDAs, and for what.

Understand generic companies’ product line up.

Monitor the financial performance of leading generics players.

Track the twists and turns of litigation.

Stay in touch with the latest M&A and strategic alliances

Contents Include:

1. Executive Summary

2. Introduction

3. Products

4. Financial Results

Latest Yearly Results

6. Major Developments

7. Mergers, Acquisitions And Agreements

8. Litigation

Sawai Pharmaceutical was established in Osaka, in 1929. The company was incorporated in 1948, and set up manufacturing lines for OTCs in 1961. In 1965, the company changed from manufacturing OTCs to ethical pharmaceuticals. Sawai was listed on the OTC stock market in 1995, and was first listed on the Tokyo Stock Exchange in 2000.

The company deals in the export and import, manufacturing and sales of pharmaceutical products and healthcare foods. Its main products are cardiovascular drugs, gastrointestinal drugs and other metabolic drugs. Its key customers are hospitals, clinics and dispensing pharmacies across Japan.

In January 2006, Sawai announced it had won a lawsuit filed by Eisai regarding Sawai’s teprenone product, Seftac. The lawsuit had been brought before the Tokyo District Court in March 2005, and was based on Japan’s Unfair Competition Prevention Law.

In July 2006, Sawai’s shares surged on market rumours that the company was shortly to be the subject of a takeover by Teva. Sawai quickly denied the rumours, although Teva had yet to comment at the time of writing.

For more information visit http://www.researchandmarkets.com/reports/c40749

Laura Wood

Senior Manager

Research and Markets

Fax: +353 1 4100 980

# # #

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Related Generic Otc Drugs Press Releases

Technorati Tags: 2006, Company, July, Market, Rumours, Sawai's, Shares, Shortly, subject, Surged, Takeover, Teva